Patents Examined by Nancy A. Johnson
  • Human matrilin-3
    Patent number: 5981263
    Abstract: The invention provides a human matrilin-3 (MAT-3) and polynucleotides which identify and encode MAT-3. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of MAT-3.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: November 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah, Matthew Kaser
  • Preimplantation factor
    Patent number: 5981198
    Abstract: A factor that indicates fertilization of an ovum before implantation, Preimplantation Factor (PIF), has been found. PIF also provides an early indication of pregnancy, malignancy, and autoimmune diseases. Assays for PIF are described. Detection of PIF in mammalian blood and other fluids is utilized in various diagnostic tests.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: November 9, 1999
    Inventors: Eytan R. Barnea, Carolyn B. Coulam
  • Vesicle transport related protein
    Patent number: 5976865
    Abstract: The invention provides a human vesicle transport related protein (VTRP) and polynucleotides which identify and encode VTRP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of VTRP.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Neil C. Corley, Purvi Shah
  • Immunoassay for the detection of MIA
    Patent number: 5973123
    Abstract: The subject matter of the present invention are high-affinity monoclonal antibodies against MIA (Melanoma inhibitory activity) in native conformation, which can be used for the detection of malignant melanomas, their use for the detection of MIA as well as immunoassays for the detection of MIA.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: October 26, 1999
    Assignee: Roche Diagnostics GmbH
    Inventors: Brigitte Kaluza, Iise Bartke, Helmut Lenz, Martin Kaufmann, Reinhard Buttner, Anja-Katrin Bosserhoff
  • Method for treating multiple sclerosis
    Patent number: 5958409
    Abstract: A method for treating multiple sclerosis, through the administration of anti-tumour necrosis factor antibody, of soluble tumour necrosis factor receptor or of a compound capable of blocking tumour necrosis factor production, its effects and/or tumour necrosis factor receptor signal transduction, is disclosed. The method can be used to aid in therapy for humans and other mammals.
    Type: Grant
    Filed: March 13, 1996
    Date of Patent: September 28, 1999
    Assignee: Kennedy Institute of Rheumatology
    Inventors: John Leslie Turk, David Baker, Marc Feldmann
  • Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay
    Patent number: 5955582
    Abstract: Methods of preparing a boronate-antigen complex for immunization of animals, a monoclonal antibody specific for the same, an immunoassay method for detection of the complex and a method of calculating the amount of a target glycated protein within the sample useful in the diagnostic monitoring of diabetes are disclosed. An immunoassay kit based on this reagent is also disclosed.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: September 21, 1999
    Assignee: Beckman Coulter, Inc.
    Inventors: Karel Z. Newman, Bruce Odegaard, Godwin Orji Ogbonna, Jane A. Schmidt
  • Antibodies to cGMP-binding, cGMP-specific phospodiesterase
    Patent number: 5955583
    Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Antibodies to the cGMP-binding, cGMP-stimulated phosphodiesterase are disclosed. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 21, 1999
    Assignees: ICOS Corporation, Board of Regents of the University of Washington, Vanderbilt University
    Inventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
  • Immunoadsorbent reagents
    Patent number: 5948894
    Abstract: Improved affinity purification media are provided by the use of small specific binding agents, especially Fv antibody fragments or single domain antibody fragments, immobilised on porous carriers having pore sizes in the range 30-1000 angstroms, preferably 30-300 angstroms. Silica is a preferred carrier. The small fragments are able to penetrate the pores and maximise the effective surface area of the carrier, and the microporous silica is sufficiently robust to be used at high pressure, so enabling the speed and/or throughput of a purification procedure to be increased.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 7, 1999
    Assignee: Unilever Patent Holdings B.V.
    Inventors: Mark J Berry, Paul J Davis, Martine E Verhoeyen, Ronald F. J. De Winter
  • Human longevity-assurance protein homologs
    Patent number: 5945330
    Abstract: The invention provides two human longevity-assurance protein homologs, designated individually as LAPH-1 and LAPH-2 and collectively as LAPH, and polynucleotides which identify and encode LAPH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of LAPH.
    Type: Grant
    Filed: July 30, 1997
    Date of Patent: August 31, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah, Preeti Lal
  • GA 20-oxidase gene sequences
    Patent number: 5939539
    Abstract: The invention relates to the molecular cloning and expression of a gibberelin (GA) 20-oxidase gene and its use, for example in transgenic plants. Aspects of the invention include recombinant DNA which encodes a polypeptide exhibiting GA 20-oxidase activity, a recombinant polypeptide exhibiting GA 20-oxidase activity, and transgenic plants which express a GA 20-oxidase gene or reverse GA 20-oxidase sequences.
    Type: Grant
    Filed: November 27, 1995
    Date of Patent: August 17, 1999
    Assignee: Long Ashton Research Station
    Inventors: Theodor Lange, Jan E. Graebe, Peter Hedden, Andrew Phillips
  • Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
    Patent number: 5935576
    Abstract: The present invention relates to immunogenic complexes of heat shock proteins (hsp) noncovalently bound to exogenous antigenic molecules which when administered to an individual elicit specific immunological responses in the host. Methods of prevention and treatment of cancer and infectious disease are provided.
    Type: Grant
    Filed: September 13, 1995
    Date of Patent: August 10, 1999
    Assignee: Fordham University
    Inventor: Pramod K. Srivastava
  • Annexin binding protein
    Patent number: 5932712
    Abstract: The invention provides a human annexin binding protein (NABP-1) and polynucleotides which identify and encode NABP-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NABP-1.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: August 3, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
  • Methods of treating TNF.alpha.-mediated disease using chimeric anti-TNF antibodies
    Patent number: 5919452
    Abstract: Treatment of tumor necrosis factor, TNF, mediated pathologies is provided by administering anti-TNF compounds, such as anti-TNF antibodies and anti-TNF peptides, which compounds are specific for tumor necrosis factor-.alpha. (TNF.alpha.) or tumor necrosis factor-.beta. (TNF.beta.) and which are useful for in vivo therapy or diagnosis of TNF.alpha.-mediated pathologies and conditions, wherein the anti-TNF compound is selected from the group consisting of at least one of an immunoglobulin variable region, a fragment of a TNF receptor and an anti-TNF peptide, such as a structural analog of a anti-TNF antibody fragment or a TNF receptor fragment.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: July 6, 1999
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Dadonna, John Ghrayeb, David Knight, Scott Seigal
  • Methods and compositions for enhancing cellular response to TGF-.beta. ligands
    Patent number: 5912224
    Abstract: The present invention concerns the TGF-.beta. receptor-mediated signaling pathway. The invention is based on the unexpected finding that TGF-.beta. receptor-mediated signaling is inhibited by the cytoplasmic interactor FKBP12. The invention further concerns methods and pharmaceutical compositions for enhancing cellular response to TGF-.beta. ligands. A screening assay is also provided for identifying macrolide potentiators capable of binding FKBP12 and thereby blocking FKBP12-inhibition of TGF-.beta. receptor-mediated signaling.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: June 15, 1999
    Assignee: The General Hospital Corporation
    Inventors: Patricia K. Donahoe, Tongwen Wang
  • Endowing lymphocytes with antibody specificity
    Patent number: 5912172
    Abstract: There are produced recombinant gene pairs which endow mononuclear cells, mainly various lymphocyte type cells, with antibody-type specificity. In specific gene pairs the rearranged gene pairs code for a binding site of an antibody molecule from the same species, of the T-cell receptor gene, or another species. Gene pairs of the invention code, for example, for antibodies specific towards tumor-specific antigens, viral antigens, modified self antigens, bacterial or fungal antigens, autoimmune type disease antigens and the like. The invention further relates to expression vectors for the effective transfection of such cell types comprising such a recombinant gene pair, to methods for producing same and to pharmaceutical compositions comprising as active ingredient an effective quantity of lymphocytes transfected with such gene pairs.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 15, 1999
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Zelig Eshhar, Gideon Gross, Tova Waks
  • Endowing lymphocytes with antibody specificity
    Patent number: 5906936
    Abstract: There are produced recombinant gene pairs which endow mononuclear cells, mainly various lymphocyte type cells, with antibody-type specificity. In specific gene pairs the rearranged gene pairs code for a binding site of an antibody molecule from the same species, of the T-cell receptor gene, or another species. Gene pairs of the invention code, for example, for antibodies specific towards tumor-specific antigens, viral antigens, modified self antigens, bacterial or fungal antigens, autoimmune type disease antigens and the like. The invention further relates to expression vectors for the effective transfection of such cell types comprising such a recombinant gene pair, to methods for producing same and to pharmaceutical compositions comprising as active ingredient an effective quantity of lymphocytes transfected with such gene pairs.
    Type: Grant
    Filed: May 4, 1993
    Date of Patent: May 25, 1999
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Zelig Eshhar, Gideon Gross, Tova Waks
  • Immuno-stimulatory monoclonal antibodies
    Patent number: 5897862
    Abstract: A monoclonal antibody having immuno-stimulatory effects, binds specifically to B lymphoblastoid cells and induces proliferation and activation of peripheral blood lymphocytes, and when injected into tumor-bearing animals elicts an anti-tumor effect.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: April 27, 1999
    Assignee: Mor Research Applications Ltd.
    Inventors: Britta Hardy, Avraham Novogrodsky
  • Antibody to aminoterminal propeptide of type 1 procollagen, and assay method using it
    Patent number: 5895746
    Abstract: Aminoterminal propeptide of type I procollagen exists in serum in two forms: classical type I procollagen which is a heterotrimer containing two pro .alpha.1-chains and one pro .alpha.2-chain of type I procollagen, and an .alpha.1-homotrimer type I procollagen containing three identical pro .alpha.1-chains. These intact, trimeric aminoterminal propeptides may be isolated without the use of proteolytic enzymes and the resultant propeptides may be used to prepare antibodies specific for the intact trimeric propeptide, having no affinity for the monomeric form of the propeptide. Such antibodies are useful in methods of assaying intact trimeric aminoterminal propeptide of type I procollagen in serum, without false information resulting from inadvertent assay of the monomeric form of the propeptide.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 20, 1999
    Assignee: Orion-Yhtyma Oy
    Inventors: Juha Risteli, Leila Risteli, Jukka Melkko, Saila Kauppila
  • Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
    Patent number: 5891996
    Abstract: New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The hypervariable regions of both monoclonal antibodies is the following amino acid sequence: light chain:CDR-1: arg-ser-ser-gln-asn-ile-val-his-ser-asn-gly-asn-thr-tyr-leu-asp;CDR-2: lys-val-ser-asn-arg-phe-ser;CDR-3: phe-gln-tyr-ser-hys-val-pro-trp-thr.Heavy chain:CDR-1: asn-tyr-tyr-ile-tyr;CDR-2: gly-ile-asn-pro-thr-ser-gly-gly-ser-asn-phe-asn-glu-lys-phe-lys-thr;CDR-3: gln-gly-leu-trp-phe-asp-ser-asp-gly-arg-gly-phe-asp-phe.Use of the antibodies for therapeutical and diagnostic purposes.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: April 6, 1999
    Assignee: Centro de Inmunologia Molecular
    Inventors: Cristina Maria Mateo de Acosta del Rio, Rolando Perez Rodriguez, Ernesto Moreno Frias
  • Method for quantifying LBP in body fluids
    Patent number: 5891618
    Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: April 6, 1999
    Assignee: XOMA Corporation
    Inventors: Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-kuen Ma